101,502 Shares in GH Research PLC (NASDAQ:GHRS) Bought by Diadema Partners LP

Diadema Partners LP bought a new stake in GH Research PLC (NASDAQ:GHRS - Free Report) during the fourth quarter, according to its most recent filing with the SEC. The firm bought 101,502 shares of the company's stock, valued at approximately $711,000. Diadema Partners LP owned about 0.20% of GH Research at the end of the most recent quarter.

Separately, Geode Capital Management LLC grew its position in shares of GH Research by 4.5% in the fourth quarter. Geode Capital Management LLC now owns 72,513 shares of the company's stock valued at $508,000 after purchasing an additional 3,092 shares during the last quarter. Institutional investors and hedge funds own 56.90% of the company's stock.

GH Research Stock Performance

Shares of GHRS stock traded up $0.03 during trading hours on Friday, hitting $9.53. The company had a trading volume of 83,428 shares, compared to its average volume of 173,808. The firm has a market capitalization of $495.83 million, a price-to-earnings ratio of -12.06 and a beta of 0.84. GH Research PLC has a 12 month low of $6.00 and a 12 month high of $20.50. The firm's fifty day moving average is $10.54 and its 200 day moving average is $9.67.

GH Research (NASDAQ:GHRS - Get Free Report) last posted its earnings results on Thursday, February 27th. The company reported ($0.17) earnings per share for the quarter, topping the consensus estimate of ($0.23) by $0.06. On average, sell-side analysts expect that GH Research PLC will post -0.8 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

GHRS has been the subject of several recent analyst reports. Stifel Nicolaus increased their target price on GH Research from $18.00 to $32.00 and gave the company a "buy" rating in a research note on Thursday, February 27th. Royal Bank of Canada started coverage on GH Research in a research report on Friday, March 7th. They issued an "outperform" rating and a $31.00 price objective for the company. Guggenheim assumed coverage on shares of GH Research in a research report on Thursday, March 13th. They set a "buy" rating and a $32.00 target price on the stock. Cantor Fitzgerald started coverage on shares of GH Research in a report on Thursday, February 13th. They issued an "overweight" rating and a $14.00 price target for the company. Finally, HC Wainwright restated a "buy" rating and set a $40.00 price objective on shares of GH Research in a report on Monday, January 27th. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat, GH Research presently has an average rating of "Buy" and a consensus price target of $30.86.

GH Research Company Profile

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).